Favrot MC - Search Results

1

Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.

Blay JY, Favrot MC, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaemmerlen P, Franks CR, Philip T. Blay JY, et al. Among authors: favrot mc. Cancer Res. 1990 Apr 15;50(8):2371-4. Cancer Res. 1990. PMID: 2317822

2

[Analysis of changes in serum levels of TNF, IL-1 and IL-6 during administration of IL-2. Correlation with clinical response to treatment].

Blay JY, Négrier S, Combaret V, Merrouche Y, Mercatello A, Moskovtchenko JF, Philip T, Favrot M. Blay JY, et al. Bull Cancer. 1992;79(1):55-65. Bull Cancer. 1992. PMID: 1520953 French.

3

TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.

Favrot M, Combaret V, Blay JY, Capdeville R, Zhou DC, Clapisson G, Chouaib S, Franks CR, Philip T. Favrot M, et al. Eur Cytokine Netw. 1990 Oct-Nov;1(4):221-7. Eur Cytokine Netw. 1990. PMID: 2104243

4

Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.

Favrot M, Capdeville R, Combaret V, Zhou DC, Clapisson G, Banchereau J, Franks CR, Chouaib S, Blay JY, Philip T. Favrot M, et al. Eur Cytokine Netw. 1990 Aug-Sep;1(3):141-7. Eur Cytokine Netw. 1990. PMID: 2129798

5

[Adoptive immunotherapy with interleukin 2 in oncology].

Favrot M, Bouffet E, Négrier S, Combaret V, Philip I, Philip T. Favrot M, et al. Bull Cancer. 1990;77(9):925-31. Bull Cancer. 1990. PMID: 2224165 Clinical Trial. French.

6

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.

Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M. Blay JY, et al. Int J Cancer. 1997 Jul 29;72(3):424-30. doi: 10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r. Int J Cancer. 1997. PMID: 9247285 Clinical Trial.

7

Tumor necrosis factor as an autocrine growth factor for neuroblastoma.

Goillot E, Combaret V, Ladenstein R, Baubet D, Blay JY, Philip T, Favrot MC. Goillot E, et al. Among authors: favrot mc. Cancer Res. 1992 Jun 1;52(11):3194-200. Cancer Res. 1992. PMID: 1317260

8

Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.

Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T. Favrot MC, et al. J Biol Response Mod. 1990 Apr;9(2):167-77. J Biol Response Mod. 1990. PMID: 1971303

9

Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.

Favrot MC, Coze C, Combaret V, Gaspard M, Colin C, Franks C, Negrier S, Philip I, Philip T. Favrot MC, et al. Mol Biother. 1990 Mar;2(1):32-7. Mol Biother. 1990. PMID: 2185792 Clinical Trial.

10

Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.

Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY. Voorzanger N, et al. Among authors: favrot mc. Cancer Res. 1996 Dec 1;56(23):5499-505. Cancer Res. 1996. PMID: 8968107

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters